<DOC>
	<DOCNO>NCT00161018</DOCNO>
	<brief_summary>The purpose study : 1 . Evaluate efficacy safety new antipsychotic , quetiapine ( 300-500mg/day ) risperidone ( 3-4mg/day ) compare fluphenazine ( 10-15mg/day ) , high potency typical antipsychotic patient meet DSM IV criterion schizophrenia . 2 . To evaluate efficacy safety quetiapine ( 1200mg/day ) patient respond conventional new antipsychotic . 3 . To evaluate effectiveness quetiapine ( 300-500mg/day ) , risperidone ( 3-5mg/day ) compare fluphenazine ( 10-15mg/day ) treatment hostility aggression treatment-resistant schizophrenic patient . 4 . To evaluate effectiveness quetiapine ( 300-500mg/day ) risperidone ( 3-5mg/day ) compare fluphenazine ( 10-15mg/day ) rate discharge , quality life , independent living skill . 5 . To assess prolactin level evaluate relationship sexual dysfunction menstrual irregularity . 6 . To evaluate possible differential impact treatment condition cognitive function include measure attention , motor speed , problem solving , verbal visual memory , verbal processing speed . 7 . To measure change weight health consequence associate weight change .</brief_summary>
	<brief_title>New Antipsychotic Strategies : Quetiapine Risperidone vs. Fluphenazine Treatment Resistant Schizophrenia</brief_title>
	<detailed_description>This three arm multi-center randomize double-blind study . After open label treatment individual optimize routine antipsychotic treatment 4-6 week prospectively establish lack response conventional antipsychotic therapy , approximately 180 patient schizophrenia experience clinically significant psychotic symptom recruit ( minimum 150 enrol ) double-blind period study . All participant sign consent form participate research study . If participant choose enroll high dose quetiapine arm ( period IIIb ) , sign additional consent form enter period IIIb .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Fluphenazine</mesh_term>
	<mesh_term>Fluphenazine depot</mesh_term>
	<mesh_term>Fluphenazine enanthate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Males Females , age 18 65 year sof age . Females childbearing potential must agree use medically accept mean contraception . A diagnosis schizophrenia accord DSMIV . Subjects must meet retrospective criterion treatmentresistance define : 1 . Persistent positive psychotic symptom . 2 . Current presence least moderately severe illness rat total BPRS . 3 . Persistence illness No evidence good function last five year . 4 . Drugrefectory condition define least two period treatment precede significant symptom relief . Subjects must judge competent consent ESC evaluation provide voluntary informed consent . Subjects must reliable . They must agree cooperate test examination require protocol . Patients msut normal ophthalmoscopic exam within 6 month full eye exam lense abnormality prior enter study . Females either pregnant lactating . Serious medical illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease hospitalization disease anticipate within three month death anticipate three year . History severe allergy multiple adverse drug reaction . DSMIV substance abuse dependence within past month . Any DSMIV organic mental disorder . Judged clinically serious suicidal risk . Definitive failure show clinically significant response ( improve CGI score least 1 point ) adequate trial clozapine ( 600mg/day least 6 week ) Uncontrolled seizure within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>